The lifetime medical cost savings from preventing HIV in the United States

Medical Care

Volumn 53, Issue 4, 2015, Pages 293-301

  Schackman, Bruce R ^a   Fleishman, John A ^b   Su, Amanda E ^c   Berkowitz, Bethany K ^c   Moore, Richard D ^d   Walensky, Rochelle P ^c,e,f   Becker, Jessica E ^c   Voss, Cindy ^d   Paltiel, A David ^g   Weinstein, Milton C ^h   Freedberg, Kenneth A ^c,e,h,i   Gebo, Kelly A ^d   Losina, Elena ^c,e,f,i  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HARVARD UNIVERSITY   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g YALE UNIVERSITY   (United States)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ BOSTON UNIVERSITY   (United States)

Author keywords

AIDS; computer modeling; health care cost; HIV; prevention

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COMPUTER SIMULATION; COST CONTROL; ETHNICITY; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LIFE EXPECTANCY; LIFESPAN; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SEXUAL TRANSMISSION; UNITED STATES; VIRUS LOAD; VIRUS TRANSMISSION; ADOLESCENT; ECONOMIC MODEL; ECONOMICS; HIV INFECTIONS; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COMPUTER SIMULATION; COST SAVINGS; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; MIDDLE AGED; MODELS, ECONOMIC; UNITED STATES; YOUNG ADULT;

EID: 84925953518     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0000000000000308     Document Type: Article

References (51)

1. Hay JW, Osmond DH, Jacobson MA. Projecting the medical costs of AIDS and ARC in the United States. J Acquir Immune Defic Syndr. 1988; 1: 466-485
2. Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA. 1993; 270: 474-478
3. Pinkerton SD, Holtgrave DR. Lifetime costs of HIV/AIDS medical care. J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 14: 380-382
4. Gebo KA, Chaisson RE, Folkemer JG, et al. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS. 1999; 13: 963-969
5. Hellinger FJ, Fleishman JA. Estimating the national cost of treating people with HIV disease: patient, payer, and provider data. J Acquir Immune Defic Syndr. 2000; 24: 182-188
6. Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001; 344: 817-823
7. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006; 44: 990-997
8. Farnham PG, Holtgrave DR, Sansom SL, et al. Medical costs averted by HIV prevention efforts in the United States, 1991-2006. J Acquir Immune Defic Syndr. 2010; 54: 565-567
9. Lasry A, Sansom SL, Hicks KA, et al. Allocating HIV prevention funds in the United States: recommendations from an optimization model. PLoS One. 2012; 7: e37545
10. US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States, 2014 clinical practice guideline: Center for Disease Control and Prevention. Available at: http://www.cdc.gov/hiv/pdf/PrEPguidelines2014.pdf. Accessed May 6, 2014
11. Schackman BR. The value of HIV screening in the United States in the era of effective treatment. Med Decis Making. 2013; 33: 457-459
12. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: Department of Health and Human Services, 2013. Available at: http://www.aidsinfo.nih.gov/contentfiles/adultandadolescentGL.pdf. Accessed May 6, 2014
13. Gebo KA. Epidemiology of HIV and response to antiretroviral therapy in the middle aged and elderly. Aging Health. 2008; 4: 615-627
14. Fleishman JA, Yehia BR, Moore RD, et al. Disparities in receipt of antiretroviral therapy among HIV-infected adults (2002-2008). Med Care. 2012; 50: 419-427
15. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS One. 2011; 6: e17502
16. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001; 344: 824-831
17. Cost-Effectiveness of Preventing AIDS Complications Web site. Available at: http://web2.research.partners.org/cepac/mainpage.html. Accessed December 18, 2013
18. HIV Research Network. Hospital and outpatient health services utilization among HIV-infected patients in care in 1999. J Acquir Immune Defic Syndr. 2002; 30: 21-26
19. Arias E. United States life tables, 2008: Centers for Disease Control and Prevention 2012. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61-03.pdf. Accessed May 26, 2014
20. Seage GR III, Holte SE, Metzger D, et al. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol. 2001; 153: 619-627
21. Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey 2009. Available at: http://meps.ahrq.gov/mepsweb/about-meps/survey-back.jsp. Accessed January 23, 2014
22. Gold MR. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996
23. Losina E, Schackman BR, Sadownik SN, et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: Impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis. 2009; 49: 1570-1578
24. Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009; 58: 1-207
25. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: Virologic, immunologic, and morphologic changes-A 96-week analysis. J Acquir Immune Defic Syndr. 2006; 43: 535-540
26. Fleishman JA, Gebo KA, Reilly ED, et al. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. Med Care. 2005; 43: III40-III52
27. Gebo KA, Fleishman JA, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era. AIDS. 2010; 24: 2705-2715
28. Thompson PDR. Red Book. Montvale, NJ: Thompson PDR; 2009
29. United States Department of Labor. Measuring price change for medical care in the CPI, 2010. Available at: http://www.bls.gov/cpi/cpifact4. htm. Accessed June 23, 2014
30. National Technical Information Service. Multicenter AIDS Cohort Study (MACS) Public Dataset: Release P04. Springfield, VA: National Technical Information Service; 1995
31. Samet JH, Freedberg KA, Savetsky JB, et al. Understanding delay to medical care for HIV infection: The long-Term non-presenter. AIDS. 2001; 15: 77-85
32. Hirsch JD, Gonzales M, Rosenquist A, et al. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS. J Manag Care Pharm. 2011; 17: 213-223
33. Morris BL, Scott CA, Wilkin TJ, et al. Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: Guidance for drug development. HIV Clin Trials. 2012; 13: 1-10
34. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012; 379: 2439-2448
35. Althoff KN. Personal communication to K. Gebo requesting NAACCORD data for CD4 count at presentation to care stratified by race, sex, and risk group (2007 data). 2012
36. Althoff KN, Gange SJ, Klein MB, et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. 2010; 50: 1512-1520
37. Department of Health and Human Services. Office of Inspector General. AIDS drug assistance program cost containment strategies, 2000. Available at: http://oig.hhs.gov/oei/reports/oei-05-99-00610.pdf. Accessed March 26, 2014
38. Centers for Medicare and Medicaid Services. Physician fee schedule search, 2009. Available at: http://www.cms.hhs.gov/PFSlookup/02-PFSSearch.asp. Accessed June 21, 2014
39. Walensky RP, Sax PE, Nakamura YM, et al. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med. 2013; 158: 84-92
40. Prabhu VS, Hutchinson AB, Farnham PG, et al. Sexually acquired HIV infections in the United States due to acute-phase HIV transmission: an update. AIDS. 2009; 23: 1792-1794
41. Pinkerton SD. How many sexually-Acquired HIV infections in the USA are due to acute-phase HIV transmission?. AIDS. 2007; 21: 1625-1629
42. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006; 43: 27-34
43. Gopalappa C, Farnham PG, Hutchinson AB, et al. Cost effectiveness of the National HIV/AIDS strategy goal of increasing linkage to care for HIV-infected persons. J Acquir Immune Defic Syndr. 2012; 61: 99-105
44. Farnham PG, Holtgrave DR, Gopalappa C, et al. Lifetime costs and quality-Adjusted life years saved from HIV prevention in the test and treat era. J Acquir Immune Defic Syndr. 2013; 64: e15-e18
45. Sloan CE, Champenois K, Choisy P, et al. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS. 2012; 26: 45-56
46. Nakagawa F, Lodwick RK, Smith CJ, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS. 2012; 26: 335-343
47. High KP, Brennan-Ing M, Clifford DB, et al. HIV and aging: state of knowledge and areas of critical need for research. J Acquir Immune Defic Syndr. 2012; 60(suppl 1): S1-18
48. Chu C, Umanski G, Blank A, et al. Comorbidity-related treatment outcomes among HIV-infected adults in the Bronx, NY. J Urban Health. 2011; 88: 507-516
49. Linas BP, Barter DM, Leff JA, et al. The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients. AIDS. 2014; 28: 365-376
50. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, aging, and non-AIDS related morbidity. BMJ. 2009; 338: a3172
51. Celum C, Baeten JM, Hughes JP, et al. Integrated strategies for combination HIV prevention: principles and examples for men who have sex with men in the Americas and heterosexual African populations. J Acquir Immune Defic Syndr. 2013; 63(suppl 2): S213-S2201